Aditya Bardia, MD, MPH, on Clinical Implications of Prescribing Sacituzumab Govitecan for Triple-Negative Breast Cancer

Posted: Monday, October 19, 2020

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses the positive phase III ASCENT trial results and what clinicians need to bear in mind when prescribing the antibody-drug conjugate sacituzumab govitecan-hziy for patients with previously treated metastatic triple-negative breast cancer.